Latest news with #MedTech
Yahoo
30 minutes ago
- Business
- Yahoo
UBS Shrugs Abbott Laboratories' (ABT) Diagnostic Weakness Affirms ‘Buy' Rating
Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty. On July 21, UBS reiterated a 'Buy' rating and a $148 price target on the stock. The bullish stance comes on the heels of the stock coming under pressure following the release of lower fiscal year 2025 sales guidance. The biopharmaceutical company is facing weakness in its diagnostic segment. However, the weakness has not altered UBS's positive stance on the company. That's because the company is experiencing robust growth, with its MedTech division recording 12.2% organic growth in the second quarter, higher than the consensus estimate of 11.2%. In addition, UBS is buoyed by Abbott's 6.9% organic sales growth or 7.5% on excluding COVID diagnostics. The research firm expects robust growth in other segments, including the MedTech pipeline, to offset weakness in the diagnostic segment. Abbott Laboratories (NYSE:ABT) is a global healthcare company focused on creating life-changing technologies and products that span diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. It is focused on improving health and well-being across all stages of life through innovative solutions and a commitment to accessibility. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best 52-Week High Stocks to Buy Now and 10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
8 hours ago
- Business
- Globe and Mail
Can Robust Invisalign Momentum Drive Align Technology's Q2 Earnings?
Align Technology, Inc. ALGN is set to release second-quarter 2025 results on July 30, after the closing bell. The company posted adjusted earnings per share (EPS) of $2.13 in the last reported quarter, which topped the Zacks Consensus Estimate by 7.6%. Align Technology beat on earnings in each of the trailing four quarters, the average surprise being 3.40%. ALGN's Q2 Estimates The Zacks Consensus Estimate for revenues is pegged at $1.06 billion, which suggests a rise of 3.2% from the year-ago reported figure. The Zacks Consensus Estimate for earnings is pinned at $2.57 per share, which implies a 6.6% rise from the year-ago recorded actuals. Estimate Revision Trend Ahead of ALGN's Q2 Earnings Estimates for second-quarter earnings have remained unchanged at $2.57 per share in the past 30 days. Let's take a look at how things might have shaped up for the MedTech major prior to the announcement. Factors at Play Clear Aligner Business Similar to the last reported quarter, Align Technology is likely to have witnessed strength in Clear Aligner volumes for teens and adult patient, reflecting growth across regions, especially APAC and EMEA. Growth in the APAC and EMEA regions is likely to have been driven the orthodontic and GP dentist channels across teens, kids and adult patients. Meanwhile, we expect Clear Aligner volume growth in in North America to have persisted in the to-be-reported quarter, driven by growth in Invisalign DSP touch-up cases, Invisalign Palate Expander system, as well as Invisalign Comprehensive Three and Three. In the first quarter, Clear Aligner volume from DSO customers increased year over year, reflecting growth across all regions. The DSO business in the United States continued to outpace the retail doctors, driven by the company's largest DSO partners — SmileDoctors and Heartland Dental. This might have benefited the company's quarterly top line. In the second quarter, its Invisalign Palatal Expander System received approval from the National Medical Products Administration ('NMPA') in China. Additionally, Align Technology introduced the Invisalign System with mandibular advancement featuring occlusal blocks. It is designed to address Class II skeletal and dental correction by simultaneously advancing the mandible while aligning the teeth. The system is commercially available in the United States, Canada, Australia and New Zealand. These factors, too, might have aided Align Technology's second-quarter revenues. Align Technology, Inc. Price and EPS Surprise Align Technology, Inc. price-eps-surprise | Align Technology, Inc. Quote Imaging Systems & CAD/CAM Service Business The Systems & Services business is projected to have witnessed growth in the second quarter due to increased scanner volumes and non-system revenues driven by iTero Lumina wand upgrades. The continuous uptake of the iTero Lumina Scanner with ortho workflow and positive response from customers are likely to have boosted the company's revenues. In the previous quarter, Align Technology launched its next-generation iTero Lumina solutions with comprehensive capabilities, including the Near Infra-Red Imaging technology in the iTero Lumina Pro dental imaging system. Also, it launched Align X-ray Insights — a new software-based computer-aided detection solution that uses artificial intelligence (AI) to automatically analyze 2D radiographs — in the EU countries and the United Kingdom. We expect these developments to have positively impacted the company's second-quarter top line. What Our Quantitative Model Predicts for ALGN Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, that is not the case here, as you can see below: Earnings ESP: Align Technologies has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #2. Stocks Worth a Look Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle: CVS Health CVS has an Earnings ESP of +2.06% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2025 results on July 31. You can see the complete list of today's Zacks #1 Rank stocks here. CVS' earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.08%. The Zacks Consensus Estimate for second-quarter EPS implies a year-over-year decline of 19.7%. Cencora COR has an Earnings ESP of +1.49% and a Zacks Rank #2 at present. The company is slated to release third-quarter fiscal 2025 results on Aug. 6. The company's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.00%. The Zacks Consensus Estimate for fiscal third-quarter EPS implies a year-over-year increase of 13.2%. Cardinal Health CAH has an Earnings ESP of +0.68% and a Zacks Rank #2 at present. The company is expected to release fiscal fourth-quarter 2025 results on Aug. 12. CAH's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.30%. The Zacks Consensus Estimate for fiscal fourth-quarter EPS suggests a year-over-year improvement of 1.3%. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Align Technology, Inc. (ALGN): Free Stock Analysis Report Cardinal Health, Inc. (CAH): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis Report
Yahoo
9 hours ago
- Business
- Yahoo
Azenta to Participate in 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
BURLINGTON, Mass., July 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, on Tuesday, August 12, 2025. About Azenta Life Sciences Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey. Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit INVESTOR CONTACTS:Yvonne PerronVice President, Financial, Planning & Analysis and Investor Relationsir@ Sherry View original content to download multimedia: SOURCE Azenta
Yahoo
18 hours ago
- Business
- Yahoo
BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived products for advanced wound care, announces it will release its second quarter 2025 financial results on Thursday, August 14, 2025, and host a conference call and webcast at 4:30 PM ET. The webcast will feature a review of second quarter results and an update on the Company's Form 10 filing and Nasdaq uplisting, led by CEO Jason Matuszewski and CFO Michael Fortunato. To register for the event, please click HERE. Conference Call & Webcast Information: Conference ID: 9695874 North America Toll-Free: (800) 715-9871 International Toll: +1 (646) 307-1963 Webcast Link: Join BioStem's Distribution List & Social Media: To follow the latest developments at BioStem, sign up for the Company's email distribution list HERE, and follow us on X and LinkedIn. About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for advanced wound care. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem's quality management systems and standard operating procedures are accredited by the American Association of Tissue Banks ('AATB') and adhere to Good Tissue Practices (cGTP) and Good Manufacturing Processes ('cGMP'). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®, American Amnion™ and American Amnion™ AC. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit Forward-Looking Statements: Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'believe,' 'expect,' 'estimate', 'plan,' 'outlook,' 'project,' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects, and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company's products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company's ability to maintain production of its products in sufficient quantities to meet demand. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Contact BioStem Technologies, Inc.: BioStem Technologies, HoldsworthDirector of Investor Relations E-Mail: adam@ Phone: 917-497-9287 Or Gilmartin GroupPhilip Trip Taylor, PrincipalE-Mail: philip@ 415-937-5406Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Cision Canada
2 days ago
- Business
- Cision Canada
ClariMed Inc. Achieves ISO 13485:2016 Certification, Strengthening Global Medical Device Development Capabilities Français
CHADDS FORD, Pa., July 29, 2025 /CNW/ -- ClariMed, Inc., a global leader in human-centered medical device development and regulatory services, today announced it has achieved ISO 13485:2016 certification through BSI, marking a significant milestone in the company's commitment to quality excellence and global expansion. The certification positions ClariMed to deliver enhanced value to MedTech and pharmaceutical companies—from innovative startups to global multinationals—while maintaining the highest standards of quality management. The certification scope encompasses consultancy services in the area of quality management systems, regulatory affairs, design and development for medical devices and in-vitro diagnostic medical device manufacturers, validating ClariMed's comprehensive service portfolio. This certification represents a transformative milestone that expands ClariMed's capabilities to serve the evolving needs of the global MedTech and pharmaceutical industries. As regulatory requirements continue to evolve globally, this certification empowers ClariMed to deliver an expanded portfolio of services—from human factors research and usability studies to strategic advisory, quality management, and digital solutions—all unified by rigorous quality standards that accelerate clients' path to market. "This certification is a testament to our team's dedication and the quality processes we have built as a collective team over the past 3 years," said Kelley Kendle, CEO of ClariMed."As we've grown to 70 talented professionals across five global offices, maintaining consistent quality standards has been paramount. ISO 13485 provides our clients with confidence that whether they're working with our teams in the US, UK, or anywhere else, they'll receive the same exceptional level of service and quality." The certification enables ClariMed to: Strengthen credibility for regulatory submissions to FDA, EU MDR, and other global regulatory bodies Minimize project risks through standardized, auditable processes Deliver consistent, high-quality deliverables across all office locations To leverage our ISO 13485 certification for clients Ensure quality is built into every project Liz Wellwood, Director of Quality at ClariMed, who spearheaded the certification effort, emphasized the operational benefits: " Our ISO 13485 certification formalizes the rigorous processes we've always maintained while introducing new efficiencies. Clients can expect enhanced traceability, risk-based decision making, and documented evidence of our commitment to continuous improvement. This certification assures them that our quality standards match their own, making collaboration more efficient and compliance more straightforward." The certification particularly benefits ClariMed's expanding global operations, with offices in Chadds Ford (PA), Cambridge (MA), San Jose (CA), Cambridge (UK), and Leeds (UK). It ensures consistent quality standards across all locations while supporting the company's mission to make innovative, user-centered medical technologies accessible to all communities. ClariMed's ISO 13485-certified quality management system strengthens its global medical device development capabilities through: Comprehensive documentation control and records management Structured training programs ensuring team expertise in latest regulatory guidance Risk-based supplier management processes End-to-end oversight and traceability of project documentation and deliverables Continuous monitoring and improvement mechanisms This certification marks a pivotal moment in ClariMed's evolution, positioning the company to meet the growing demand for sophisticated, globally-compliant medical device development services. As the industry continues to globalize, ClariMed's ISO 13485 certification ensures clients have a trusted partner capable of delivering consistent excellence across borders and regulatory jurisdictions. About ClariMed ClariMed is a premier human-centered medical device development and regulatory services company that accelerates time to market, enhances patient safety, and enables innovation for pharmaceutical and MedTech teams. Our unique approach integrates human factors at the core of device development and regulatory pathways, ensuring a "quality by design" process that maximizes value for patients, customers, and shareholders. Visit us at
